amorchem header logo close button Menu
arrow leftBack to portfolio

Mperia Therapeutics

Mperia Therapeutics (www.mperiathera.com) is a biotech company spun out from our CD36 programs with Dr. Ong and his collaborators from the Université de Montréal. Mperia focuses on the development of CD36-mediated immunomodulators to prevent and reverse macrophage-driven inflammation such as is seen in the dry form of age-related macular degeneration (dry AMD), atherosclerosis and non-alcoholic steatohepatitis (NASH). The combined accumulation and oxidation of lipids trigger aberrant signaling and macrophage dysfunction, and CD36 is a key mediator of these ensuing inflammation. Mperia’s MPE-298 lead candidate corrects this dysfunction, dampers the inflammation as well as reverses the cell damages caused by macrophage infiltration.